Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.
Nancy Lin, MD, discusses the impact of neratinib (Nerlynx) on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer.
This analysis presented at the 2019 San Antonio Breast Cancer Symposium pulled together CNS data from the NALA, NEfERT-T, and TBCRC 022 trials, explains Lin. The phase III NALA trial comparing lapatinib (Tykerb) plus capecitabine versus neratinib plus capecitabine in patients with HER2-positive, pretreated, metastatic breast cancer. The NEfERT-T trial compared first-line neratinib plus paclitaxel versus trastuzumab paclitaxel in HER2-positive metastatic breast cancer. Finally, the TBCRC 022 trial was a single-arm multi-cohort study specifically enrolling patients with progressive CNS disease. In that study, the primary endpoint was CNS objective response.
The goal of analyzing the data from these 3 trials was to compile the CNS-focused data in 1 place, focusing on CNS progression and response, concludes Lin.